KR960033456A - Antistress Pharmaceutical Composition - Google Patents

Antistress Pharmaceutical Composition Download PDF

Info

Publication number
KR960033456A
KR960033456A KR1019950006225A KR19950006225A KR960033456A KR 960033456 A KR960033456 A KR 960033456A KR 1019950006225 A KR1019950006225 A KR 1019950006225A KR 19950006225 A KR19950006225 A KR 19950006225A KR 960033456 A KR960033456 A KR 960033456A
Authority
KR
South Korea
Prior art keywords
acid
pharmaceutical composition
composition according
choline acids
choline
Prior art date
Application number
KR1019950006225A
Other languages
Korean (ko)
Other versions
KR0155976B1 (en
Inventor
염제호
유은주
장병수
임승옥
김점용
유영효
박명환
이병광
Original Assignee
서치영
주식회사 대웅제약
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서치영, 주식회사 대웅제약 filed Critical 서치영
Priority to KR1019950006225A priority Critical patent/KR0155976B1/en
Publication of KR960033456A publication Critical patent/KR960033456A/en
Application granted granted Critical
Publication of KR0155976B1 publication Critical patent/KR0155976B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/413—Gall bladder; Bile
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

본 발명은 콜린산류의 스트레스 예방 및 치료용 용도와 그의 약제조성물에 관한 것으로, 콜린산류로는 우루소데옥시콜린산, 타우로우루소데옥시콜린산, 체노데옥시콜린산, 디하이드로콜린산 또는 동물의 담즙중에서 선택되며, 이들을 주성분으로 하고 여기에 약제학적으로 허용가능한 담체로서 희석제, 활택제, 결합제, 붕해제, 감미제, 안정제, 방부제중에서 1종 또는 2종 이상을 선택하여 사용하고, 첨가제로서 향료, 비타민류, 항산 화제중에서 1종 또는 2종 이상을 선택, 사용하여 정제, 캅셀제, 연질캅셀제, 액제, 산제 등의 형태로 제형화한것이다.The present invention relates to the use of choline acids for the prevention and treatment of stress and pharmaceutical compositions thereof, and the choline acids include urosodeoxycholine acid, taurousodeoxycholine acid, chenodeoxycholine acid, dihydrocholine acid or It is selected from the bile of the animal, which is used as a main ingredient and one or two or more selected from diluents, lubricants, binders, disintegrants, sweeteners, stabilizers, preservatives as a pharmaceutically acceptable carrier. It is formulated in the form of tablets, capsules, soft capsules, liquids, powders, etc. by using one or two or more selected from fragrances, vitamins and antioxidants.

콜린산류는 1일 복용량은 5∼800mg 되도록하여 분복한다.Choline acids are divided into 5 to 800 mg daily doses.

Description

항스트레스 의약조성물Antistress Pharmaceutical Composition

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (12)

콜린산류로 구성된 항스트레스제.Antistress agent composed of choline acids. 제1항에 있어서, 콜린산류로는 우루소데옥시콜린산, 타우로우루소데옥시콜린산, 체노데옥시콜린산, 디하이드로콜린산중에서 선택됨을 특징으로 하는 항스트레스제.The antistress agent according to claim 1, wherein the choline acids are selected from urosodeoxycholine acid, taurousodeoxycholine acid, chenodeoxycholine acid, and dihydrocholine acid. 제1항에 있어서, 콜린산류는 동물의 담즙임을 특징으로 하는 항스트레스제.The antistress agent according to claim 1, wherein choline acids are bile of an animal. 콜린산류를 함유함을 특징으로 하는 스트레스의 예방 및 치료용 의약조성물.A pharmaceutical composition for the prevention and treatment of stress, characterized by containing choline acids. 제4항에 있어서, 콜린산류는 우루소데옥시콜린산, 타우로우루소데옥시콜린산, 체노데옥시콜린산, 디하이드로콜린산 중에서 선택됨을 특징으로 하는 의약조성물.The pharmaceutical composition according to claim 4, wherein the choline acids are selected from urosodeoxycholine acid, taurousodeoxycholine acid, chenodeoxycholine acid, and dihydrocholine acid. 제4항에 있어서, 콜린산류는 동물의 담즙임을 특징으로 하는 의약조성물.The pharmaceutical composition according to claim 4, wherein the choline acids are bile of an animal. 제4항 내지 6항 중 어느 한 항에 있어서, 1종 또는 2종 이상의 약제학적으로 허용가능한 담체 및 첨가제를 포함하는 의약조성물.The pharmaceutical composition according to any one of claims 4 to 6, comprising one or two or more pharmaceutically acceptable carriers and additives. 제7항에 있어서, 담체는 희석제, 활택제, 결합제, 붕해제, 감미제, 안정제, 방부제 중에서 1종 또는 2종이상 선택됨을 특징으로 하는 의약조성물.The pharmaceutical composition according to claim 7, wherein the carrier is selected from at least one of diluents, lubricants, binders, disintegrants, sweeteners, stabilizers, and preservatives. 제7항에 있어서, 첨가제는 향료, 비타민류, 향산화제중에서 1종 또는 2종 이상 선택됨을 특징으로 하는 의약조성물.The pharmaceutical composition according to claim 7, wherein the additive is selected from one or two or more among flavors, vitamins, and oxidizing agents. 제5항에 있어서, 콜린산류의 1일 복용량이 5∼800mg, 바람직하게는 25∼400mg임을 특징으로 하는 의약조성물.The pharmaceutical composition according to claim 5, wherein the daily dose of choline acids is 5 to 800 mg, preferably 25 to 400 mg. 제10항에 있어서, 우루소데옥시콜린산의 1일 복용량이 5∼400mg, 바람직하게는 25∼400mg임을 특징으로 하는 의약조성물.11. A pharmaceutical composition according to claim 10, wherein the daily dose of urousodeoxycholic acid is 5 to 400 mg, preferably 25 to 400 mg. 제4항에 있어서, 제형은 정제, 캅셀제, 연질캅셀제, 액제, 산제 중에서 선택됨을 특징으로 하는 의약조성물.The pharmaceutical composition according to claim 4, wherein the formulation is selected from tablets, capsules, soft capsules, solutions, and powders. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950006225A 1995-03-23 1995-03-23 Anti-stress pharmaceutical composition KR0155976B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019950006225A KR0155976B1 (en) 1995-03-23 1995-03-23 Anti-stress pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019950006225A KR0155976B1 (en) 1995-03-23 1995-03-23 Anti-stress pharmaceutical composition

Publications (2)

Publication Number Publication Date
KR960033456A true KR960033456A (en) 1996-10-22
KR0155976B1 KR0155976B1 (en) 1998-11-16

Family

ID=19410435

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950006225A KR0155976B1 (en) 1995-03-23 1995-03-23 Anti-stress pharmaceutical composition

Country Status (1)

Country Link
KR (1) KR0155976B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106804485B (en) * 2017-03-21 2019-12-17 中国水产科学研究院淡水渔业研究中心 Stress-resistant method for temporarily culturing coilia ectenes in small water body

Also Published As

Publication number Publication date
KR0155976B1 (en) 1998-11-16

Similar Documents

Publication Publication Date Title
BR9611802A (en) Pharmaceutical compositions
FR2708606B1 (en) N-phenylalkylindol-2-one derivatives, their preparation, pharmaceutical compositions containing them.
HUP9901144A2 (en) Pharmaceutical compositions containing new associations of clopidogrel and an antithrombotic agent
YU13695A (en) Application of 2-phenyl-3-aroylbenzothiophene and pharmaceutical formulations thereof
IT1187687B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AS ACTIVE INGREDIENTS FLAVANOLIGNANI AND PHOSPHOLIPIDS
KR940018089A (en) Prevention and treatment for radiation damage of internal tissue
IT1263840B (en) ORAL FORMULATIONS OF UBIDECARENONE IN THE FORM OF CAPSULES
KR970061244A (en) Pharmaceutical composition for treating dementia
IL102814A0 (en) Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them
DE60002126D1 (en) Substituted dimeric carboxamide derivatives, process for their preparation and pharmaceutical compositions containing them
KR950007857A (en) Rapamycin preparations for oral administration
KR970032872A (en) Drugs for the treatment of skin damage containing acetylsalicylic acid
KR890001564A (en) Pharmaceutical dosage unit
MX9203361A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING GALIUM CHLORIDE.
KR960033456A (en) Antistress Pharmaceutical Composition
DE3883208D1 (en) AGENTS FOR TREATING KERATOSIS.
ATE285782T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AN ALKYLARYL POLYETHER ALCOHOL POLYMER
KR960033455A (en) Anticancer composition
DE69902925T2 (en) New injectable medicinal preparations containing RAMOPLAN
KR950016756A (en) Fatigue Recovery Composition
KR950016755A (en) Pharmaceutical composition for the prevention and treatment of hepatitis
PT100526A (en) CHEMOTHERAPEUTIC AGENTS OF PLANT ORIGIN WITH ANTINEOPLASTIC ACTIVITY, POSSESSING HIGH SELECTIVITY AND VERY REDUCED TOXICITY AND PROCESS FOR THEIR PREPARATION
GB2082910A (en) Anti-depressant compositions
KR950016757A (en) Drug addiction therapeutic composition
KR910002455A (en) Pharmaceutical compositions containing acrylic acid derivatives and their use as medicaments

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130327

Year of fee payment: 16

FPAY Annual fee payment

Payment date: 20140306

Year of fee payment: 17

EXPY Expiration of term